Gregorio Rábago

Gregorio Rábago

Auto-generated profile, based on publicly available information

Gregorio Rábago

Department of Cardiology and Cardiac Surgery, Clínica Universidad de Navarra, Navarra, Spain

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2008 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MCM. G. Crespo-Leiro
M. G. Crespo-Leiro
LAL. Alonso-Pulpón
L. Alonso-Pulpón
JPJ. A. Vázquez de Prada
J. A. Vázquez de Prada
LAL. Almenar
L. Almenar
JAJ. M. Arizón
J. M. Arizón
JMJavier Muñiz
Javier Muñiz
The Spanish Post-Heart-Transplant Tumour Registry comprises data on neoplasia following heart transplantation (HT) for all Spanish HT patients (1984–2003). This retrospective analysis of 3393 patients investigated the incidence and prognosis of neoplasia, and the influence of antiviral prophylaxis. About 50% of post-HT neoplasias were cutaneous, and 10% lymphomas. The cumulative incidence of skin cancers and other nonlymphoma cancers increased with age at HT and with time post-HT (from respectively 5.2 and 8.9 per 1000 person-years in the first year to 14.8 and 12.6 after 10 years), and was greater among men than women. None of these trends held for lymphomas. Induction therapy other than with IL2R-blockers generally increased the risk of neoplasia except when acyclovir was administered prophylactically during the first 3 months post-HT; prophylactic acyclovir halved the risk of lymphoma, regardless of other therapies. Institution of MMF during the first 3 months post-HT reduced the incidence of skin cancer independently of the effects of sex, age group, pre-HT smoking, use of tacrolimus in the first 3 months, induction treatment and antiviral treatment. Five-year survival rates after first tumor diagnosis were 74% for skin cancer, 20% for lymphoma and 32% for other tumors.

26 September 2017 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
EBEduardo Barge-Caballero
Eduardo Barge-Caballero
LALuis Almenar-Bonet
Luis Almenar-Bonet
FGFrancisco Gonzalez-Vilchez
Francisco Gonzalez-Vilchez
JRJose Luis Lambert Rodriguez
Jose Luis Lambert Rodriguez
JGJosé González-Costello
José González-Costello
MCMaria G. Crespo-Leiro
Maria G. Crespo-Leiro
Background In Spain, listing for high‐urgent heart transplantation is allowed for critically ill candidates not weanable from temporary mechanical circulatory support (T‐MCS). We sought to analyse the clinical outcomes of this strategy. Methods and results We conducted a case‐by‐case, retrospective review of clinical records of 291 adult patients listed for high‐urgent heart transplantation under temporary devices from 2010 to 2015 in 16 Spanish institutions. Survival after listing and adverse clinical events were studied. At the time of listing, 169 (58%) patients were supported on veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO), 70 (24%) on temporary left ventricular assist devices (T‐LVAD) and 52 (18%) on temporary biventricular assist devices (T‐BiVAD). Seven patients transitioned from VA‐ECMO to temporary ventricular assist devices while on the waiting list. Mean time on T‐MCS was 13.1 ± 12.6 days. Mean time from listing to transplantation was 7.6 ± 8.5 days. Overall, 230 (79%) patients were transplanted and 54 (18.6%) died during MCS. In‐hospital postoperative mortality after transplantation was 33.3%, 11.9% and 26.2% for patients bridged on VA‐ECMO, T‐LVAD and T‐BiVAD, respectively (P = 0.008). Overall survival from listing to hospital discharge was 54.4%, 78.6% and 55.8%, respectively (P = 0.002). T‐LVAD support was independently associated with a lower risk of death over the first year after listing (hazard ratio 0.52, 95% confidence interval 0.30–0.92). Patients treated with VA‐ECMO showed the highest incidence rate of adverse clinical events associated with T‐MCS. Conclusion Temporary devices may be used to bridge critically ill candidates directly to heart transplantation in a setting of short waiting list times, as is the case of Spain. In our series, bridging with T‐LVAD was associated with more favourable outcomes than bridging with T‐BiVAD or VA‐ECMO.

1 December 2013 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MCMaria Dolores García Cosío Carmena
Maria Dolores García Cosío Carmena
MBManuel Gómez Bueno
Manuel Gómez Bueno
LALuis Almenar
Luis Almenar
Juan F. Delgado JiménezJuan F. Delgado Jiménez
Juan F. Delgado Jiménez
JAJose M. Arizón
Jose M. Arizón
JSJavier Segovia
Javier Segovia

1 October 2009 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
FMFrancesco Maisano
Francesco Maisano
HKHenrik K. Kjærgård
Henrik K. Kjærgård
RBRobert Bauernschmitt
Robert Bauernschmitt
APAlain Pavie
Alain Pavie
GRGregorio Rábago
Gregorio Rábago
VFVolkmar Falk
Volkmar Falk
Prolonged bleeding during cardiovascular surgery presents a risk for the patient and increases the time and cost of surgery. TachoSil is a ready-to-use haemostatic agent that consists of an equine collagen patch coated with human fibrinogen and thrombin. This trial evaluated the efficacy and safety (< or =30 days post-surgery) of TachoSil surgical patch compared with standard haemostatic fleece for the control of bleeding in patients undergoing cardiovascular surgery. Patients scheduled for elective surgery on the heart, ascending aorta or aortic arch requiring cardiopulmonary bypass were eligible for this open-label multicentre trial. After primary haemostatic measures, patients were randomised to TachoSil or conventional haemostatic fleece if an area of persisting haemorrhage was identified (target area). After the application of trial treatment, haemostasis was evaluated at 3 min (primary endpoint). If haemostasis was not achieved, trial treatment was re-applied and haemostasis assessed at 6 min (secondary endpoint). A total of 120 patients were randomised and 119 received trial treatment (TachoSil, n=59; standard treatment, n=60). Twenty-six percent of patients were female and the mean age was 67 years (range: 23-86 years). Baseline characteristics were similar in both the groups. Bleeding occurred mainly from the aorta (56%), right ventricle (16%) or right atrium (13%), more often from a vessel (68%) than tissue (32%), and was assessed to be arterial in 74% of cases. TachoSil was significantly superior to standard haemostatic fleece in controlling bleeding after insufficient primary haemostasis, with 75% (95% confidence interval (CI): 0.64-0.86) of the TachoSil group achieving haemostasis at 3 min compared with only 33% (95% CI: 0.21-0.45) of the standard treatment group (p<0.0001). This difference persisted at 6 min, with 95% of patients achieving haemostasis in the TachoSil group compared with 72% in the standard treatment group (p=0.0006). Three (5%) TachoSil patients compared with 17 (28%) standard treatment patients failed to achieve haemostasis at 6 min and received rescue treatment. TachoSil was well tolerated with adverse events generally similar in the two treatment groups. TachoSil was significantly superior to standard haemostatic fleece material in obtaining effective and fast intra-operative haemostasis in cardiovascular surgical procedures. TachoSil was safe and well tolerated.

1 October 2003 in Atherosclerosis
Verified
Journal Article
Closed access
JOJosune Orbe
Josune Orbe
LFL Fernandez
L Fernandez
JRJose Antonio Rodriguez
Jose Antonio Rodriguez
GRG Rábago
G Rábago
MBM Belzunce
M Belzunce
JPJosé A Páramo
José A Páramo

1 October 2010 in Transplantation Proceedings
Verified
Journal Article
Open access
BMBeatriz Diaz Molina
Beatriz Diaz Molina
MLM.G.C. Leiro
M.G.C. Leiro
LPL.A. Pulpón
L.A. Pulpón
SMS. Mirabet
S. Mirabet
JYJ.F. Yañez
J.F. Yañez
JMJavier Muñiz
Javier Muñiz
The incidence of skin cancer in heart transplant (HT) patients is higher than in the general population, reversing the proportion of cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) with a predominance of the former. The etiologic role of new immunosuppressants is not well known. We sought to ascertain the incidence of SCC and BCC in HT patients and the risk factors for its occurrence. We report the incidence of all types of post-HT skin cancer, SCC, and BCC among adult HT patients in Spain (4089 subjects) as well as the influence of gender, age at heart transplant, immunosuppression, and sunlight exposure. The incidence rates of SCC and BCC, per 1000 persons/year, were 8.5 and 5.2, respectively. Males had a higher risk of SCC but not BCC. Induction therapy increased the risk of SCC and BCC. The relative risk of mycophenolate mofetil (MMF) was 0.3 (0.2-0.6; P<.0005) and azathioprine (AZA) 1.8 (1.2-2.7; P<.0032) for SCC, whereas tacrolimus and cyclosporine showed no difference. The relative risk of BCC was not affected by any immunosuppressant. Age at transplantation>45 years, induction therapy use, and high sunshine zone were risk factors for both SCC and BCC. Different immunosuppressive agents have different risks of nonmelanoma skin cancer, as AZA increases the risk of SCC and MMF is a protective factor. The relative risk of BCC was not affected by any immunosuppressor.